OncoMatch/Clinical Trials/NCT06194734
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Is NCT06194734 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including KC1036 and Irinotecan for esophageal squamous cell carcinoma.
Treatment: KC1036 · Irinotecan · Docetaxel · S-1 — The purpose of this study is to evaluate the efficacy and safety of KC1036 versus investigator's choice of chemotherapy in patients with advanced recurrent or metastatic esophageal squamous cell carcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-pd-1/pd-l1 therapy
Cannot have received: vascular targeting inhibitor
Cannot have received: chemotherapy (irinotecan, docetaxel, tegafur gimeracil oteracil potassium)
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify